Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 12Colonic Neoplasms 4Neoplasms 3Rectal Neoplasms 2Pancreatic Neoplasms 2Lung Neoplasms 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Thyroid Neoplasms 1Recurrence 1Pancreatic Adenocarcinoma 1Histiocytosis 1Glioma 1Carcinoma, Squamous Cell 1Carcinoma 1

Interventions

Fluorouracil 8Oxaliplatin 7Leucovorin 6Irinotecan 6Gemcitabine 5fludarabine 3aldesleukin 3Pemetrexed 3Nivolumab 3Cyclophosphamide 3Cetuximab 3Capecitabine 35,10-methylenetetrahydrofolic acid 3dehydroftorafur 2cobimetinib 2Specimen Handling 2Panitumumab 2Interleukin-2 2Docetaxel 2Bevacizumab 2130-nm albumin-bound paclitaxel 2tivozanib 1sodium propionate 1rucaparib 1rilotumumab 1repotrectinib 1regorafenib 1pralsetinib 1pertuzumab 1pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Gastrointestinal Neoplasms × Panitumumab × Clear all
NCT05121038 2024-12-17

CENDIFOX

University of Kansas Medical Center

Phase 1/2 Active not recruiting
50 enrolled
Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms

NCT00788957 2024-08-07

Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)

NantBioScience, Inc.

Phase 1/2 Completed
177 enrolled 31 charts
Gastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡